Companion Diagnostics

Five things for pharma marketers to know: Thursday, June 2, 2016

Five things for pharma marketers to know: Thursday, June 2, 2016

By By

Pfizer releases new campaign; progressive research group calls out PCORI; U.S. drugmakers hire auditors they have ties with

Five things for pharma marketers to know: Thursday, July 30

Five things for pharma marketers to know: Thursday, July 30

Copaxone sales rise despite generic competition; Valeant to defend tax strategy; Bristol-Myers Squibb to test Opdivo with mogamulizumab in the US

Five things for pharma marketers to know: Tuesday, July 14

Five things for pharma marketers to know: Tuesday, July 14

By

The FDA approves AstraZeneca's Iressa as a first-line lung-cancer therapy; Mylan and Dr. Reddy's launch generic versions of dementia treatment Namenda; health insurer consolidation may lead to pressure on drug prices

Roche diagnostic unit partnering with drugmaker on companion diagnostic

The test seeks to identify patients with metastatic pancreatic cancer and high levels of hyaluronan.

Myriad expands companion diagnostic deals

Myriad expands companion diagnostic deals

By

The company partnered with AstraZeneca and BioMarin to identify which patients respond to experimental cancer drugs.

OPINION

Email Newsletters